APC
CNSP icon

Aspire Private Capital’s CNS Pharmaceuticals CNSP Stock Holding History

Aspire Private Capital’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$52 – 244
2024
Q3 		$52 Buy
+1
New +$287 ﹤0.01% 665

Other funds holding CNSP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aspire Private Capital's CNSP Position: Q4 2024 in Review

Aspire Private Capital sold out of CNS Pharmaceuticals (CNSP) in Q4 2024, closing a stake of 1 share — an estimated $52 sold.

Aspire Private Capital first reported a position in CNSP in Q3 2024 and held it in 1 quarter. The position peaked at $52 in Q3 2024. 13 funds tracked by Wall St. Rank hold CNSP as of Q4 2024.

  • Aspire Private Capital reported no remaining CNS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Aspire Private Capital sold 1 CNS Pharmaceuticals share in Q4 2024, an estimated $52.
  • Aspire Private Capital first reported a position in CNS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Aspire Private Capital's CNS Pharmaceuticals position peaked at $52 in Q3 2024.
  • 13 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.